Geneviève Deblois

Dr. Geneviève Deblois

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MFMarina Fukano
Marina Fukano
MPMorag Park
Morag Park
GDGeneviève Deblois
Geneviève Deblois
Breast cancer progression is characterized by changes in cellular metabolism that contribute to enhanced tumour growth and adaptation to microenvironmental stresses. Metabolic changes within breast tumours are still poorly understood and are not as yet exploited for therapeutic intervention, in part due to a high level of metabolic heterogeneity within tumours. The metabolic profiles of breast cancer cells are flexible, providing dynamic switches in metabolic states to accommodate nutrient and energy demands and further aggravating the challenges of targeting metabolic dependencies in cancer. In this review, we discuss the intrinsic and extrinsic factors that contribute to metabolic heterogeneity of breast tumours. Next, we examine how metabolic flexibility, which contributes to the metabolic heterogeneity of breast tumours, can alter epigenetic landscapes and increase a variety of pro-tumorigenic functions. Finally, we highlight the difficulties in pharmacologically targeting the metabolic adaptations of breast tumours and provide an overview of possible strategies to sensitize heterogeneous breast tumours to the targeting of metabolic vulnerabilities.

29 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
BLBenjamin Lebeau
Benjamin Lebeau
MJMaïka Jangal
Maïka Jangal
TZTiejun Zhao
Tiejun Zhao
CWCheng Kit Wong
Cheng Kit Wong
NWNolan Wong
Nolan Wong
MWMichael Witcher
Michael Witcher
The contribution of deregulated chromatin architecture, including topologically associated domains (TADs), to cancer progression remains ambiguous. CCCTC-binding factor (CTCF) is a central regulator of higher-order chromatin structure that undergoes copy number loss in over half of all breast cancers, but the impact of this defect on epigenetic programming and chromatin architecture remains unclear. We find that under physiological conditions, CTCF organizes subTADs to limit the expression of oncogenic pathways, including phosphatidylinositol 3-kinase (PI3K) and cell adhesion networks. Loss of a single CTCF allele potentiates cell invasion through compromised chromatin insulation and a reorganization of chromatin architecture and histone programming that facilitates de novo promoter-enhancer contacts. However, this change in the higher-order chromatin landscape leads to a vulnerability to inhibitors of mTOR. These data support a model whereby subTAD reorganization drives both modification of histones at de novo enhancer-promoter contacts and transcriptional up-regulation of oncogenic transcriptional networks.

1 January 2023
Verified
Book Chapter
Closed access
PDF file
MFMarina Fukano
Marina Fukano
GAGabriel Alzial
Gabriel Alzial
RLRaphaëlle Lambert
Raphaëlle Lambert
GDGeneviève Deblois
Geneviève Deblois


3 April 2023
Verified
Other
Open access
GDGeneviève Deblois
Geneviève Deblois
STSeyed Ali Madani Tonekaboni
Seyed Ali Madani Tonekaboni
GGGiacomo Grillo
Giacomo Grillo
Constanza Eugenia MartinezConstanza Eugenia Martinez
Constanza Eugenia Martinez
YKYunchi Ingrid Kao
Yunchi Ingrid Kao
MLMathieu Lupien
Mathieu Lupien
Supplementary data, figures and table

28 October 2026 in Cancer Research
Verified
Journal Article
Closed access
LPLucas Porras
Lucas Porras
MCMarina Carrière
Marina Carrière
AGAnn-Sophie Gironne
Ann-Sophie Gironne
HPHugo Philippeau
Hugo Philippeau
GAGabriel Alzial
Gabriel Alzial
GDGeneviève Deblois
Geneviève Deblois
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.